Protalix Biotherapeutics, Inc. (PLX)
3.01
-0.02
(-0.66%)
USD |
NYAM |
Feb 26, 12:43
Protalix Biotherapeutics Research and Development Expense (Quarterly) : 4.467M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Denali Therapeutics, Inc. | 101.95M |
| OraSure Technologies, Inc. | 9.592M |
| Nephros, Inc. | 0.338M |
| Agenus, Inc. | 23.60M |
| Curis, Inc. | 6.432M |